Fertility warning
This medicine may affect fertility.
Leaflet ONCASPAR 750U / ml powder for solution for injection / infusion
- Product code:
- W66172001
- Quantity:
- 1
- Indicated for:
- cancer
- Route of administration:
- injectable / infusion
- Substance:
- pegaspargase (antineoplastic agent)
- ATC
- L01XX24 — Antineoplastic and immunomodulating agents | Other antineoplastic agents
Precautions:
Dose adjustment in hepatic impairment
Dose adjustment may be needed in liver disease.
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Pegaspargase is an antineoplastic agent used in the treatment of acute lymphoblastic leukemia (ALL). It works by degrading asparagine, an amino acid essential for the growth of leukemic cells, thereby inhibiting their proliferation.
The medication is administered intravenously or intramuscularly, as directed by a doctor, usually as part of a combination chemotherapy regimen. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the therapy's effects.
Patients should be aware of potential side effects, such as allergic reactions, pancreatitis, or coagulation disorders. It is important to inform the doctor of any unusual symptoms.
Common side effects include allergic reactions, elevated liver enzymes, and coagulation disorders. In rare cases, severe reactions such as acute pancreatitis or thrombosis may occur. Patients should be informed of these risks before use.
The medication is administered intravenously or intramuscularly, as directed by a doctor, usually as part of a combination chemotherapy regimen. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the therapy's effects.
Patients should be aware of potential side effects, such as allergic reactions, pancreatitis, or coagulation disorders. It is important to inform the doctor of any unusual symptoms.
Common side effects include allergic reactions, elevated liver enzymes, and coagulation disorders. In rare cases, severe reactions such as acute pancreatitis or thrombosis may occur. Patients should be informed of these risks before use.
Official documents
- Added to database:
- 29/01/2016
- Source record updated:
- 07/05/2026
General data about ONCASPAR 750U / ml
- Substance:
- pegaspargase
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W66172001
- Concentration:
- 750U / ml
- Pharmaceutical form:
- powder for solution for injection / infusion
- Quantity:
- 1
- Product type:
- Original
- Price:
- 8303.23 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.